New insider activity at Nuvectis Pharma ( (NVCT) ) has taken place on February 12, 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Significant shareholder Marlio Charles Mosseri has made a notable investment by purchasing 240,000 shares of Nuvectis Pharma stock, with the transaction valued at $1,200,000.
Recent Updates on NVCT stock
Nuvectis Pharma recently announced the pricing of its underwritten public offering of 2.7 million shares at $5.00 each, which is below the last closing price of $7.00. The offering, managed by Lucid Capital Markets, is expected to generate gross proceeds of $13.5 million, with an option for the underwriter to purchase up to an additional 405,000 shares. The proceeds are intended to support the advancement of Nuvectis’ development programs, including NXP800 and NXP900, and cover general corporate expenses. This move comes as part of the company’s strategy to fund ongoing and future projects, which likely influenced recent stock price movements and analyst perceptions.
More about Nuvectis Pharma
YTD Price Performance: 17.44%
Average Trading Volume: 153,459
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $160.4M